DAWN
Day One Biopharmaceuticals, Inc.
A biopharmaceutical company focused on targeted cancer therapies for both children and adults. Its lead drug, Ojemda (tovorafenib), became the first FDA-approved systemic treatment for pediatric low-grade glioma, the most common childhood brain tumor. Founded in 2018 to close the "innovation gap" that left young cancer patients behind, the company takes its name from the "Day One talk" — the life-altering conversation a doctor has with a family on diagnosis day.
CUSIP: 23954D109HealthcareUS2 holders